Last reviewed · How we verify
Insulin-Levemir and Exenatide-Bayetta — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Insulin-Levemir and Exenatide-Bayetta (Insulin-Levemir and Exenatide-Bayetta) — Novo Nordisk A/S.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Insulin-Levemir and Exenatide-Bayetta TARGET | Insulin-Levemir and Exenatide-Bayetta | Novo Nordisk A/S | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Insulin-Levemir and Exenatide-Bayetta CI watch — RSS
- Insulin-Levemir and Exenatide-Bayetta CI watch — Atom
- Insulin-Levemir and Exenatide-Bayetta CI watch — JSON
- Insulin-Levemir and Exenatide-Bayetta alone — RSS
Cite this brief
Drug Landscape (2026). Insulin-Levemir and Exenatide-Bayetta — Competitive Intelligence Brief. https://druglandscape.com/ci/insulin-levemir-and-exenatide-bayetta. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab